Liquidbio

Liquidbio continues the IsoFlux legacy started by Fluxion Biosciences in 2012. 

We are as passionate about CTC liquid biopsies as you are! Liquidbio's core team pioneered the conception, development, validation, launch, applications, and customer support of the IsoFlux system, and we're thrilled to lead IsoFlux into the future.

Validated in tens of thousands of samples processed by leading labs around the world, IsoFlux continues to set the standard for circulating tumor cell (CTC) liquid biopsies.

Whether the focus is patient monitoring, biomarker research, or cancer genomic profiling by NGS, IsoFlux systems and kits set the benchmark in performance, flexibility, and ease of use.